
    
      This is an open-label (all people know the identity of the intervention), single oral-dose
      and post-marketing study of darunavir administered in combination with low-dose ritonavir in
      healthy adult Japanese male participants. The total study duration will be approximately of
      14 days per participant. The study consists of 3 parts: Screening (that is, 28 days before
      study commences on Day 1); Treatment (that is, Day 1-5); and Follow-up (that is, up to Day
      13). The participants will be hospitalized for 6 nights and 7 days. All the eligible
      participants will receive Darunavir oral tablet on Day 3 and ritonavir capsule orally twice
      daily from Day 1-5. Participants will keep upright position until 4 hours after study drug
      administration. Both the drugs will be administered within 15 minutes after completion of
      meal. Blood samples will be collected for evaluation of pharmacokinetics at pre-dose and
      post-dose of study treatment. Participants' safety will be monitored throughout the study.
    
  